XVIVO Perfusion: Q3 2026 net sales of SEK 252.6m, up 34% in SEK
FROM THE WIRE · FINANCE.YAHOO.COM
GOTHENBURG, SE / ACCESS Newswire / October 22, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Third quarter 2026 (Jul-Sep) Net sales amounted to SEK 252.6 million (189.1), corresponding to a growth of 34 percent in SEK. Organic growth was 32 percent in local…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishStrong revenue and EBITDA growth with a lower gross margin is relevant for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Organic growth was 32% in local currencies.
- 02Operating income (EBIT) rose to SEK 28.0 million from 17.9 million.
- 03Total gross margin fell to 70% from 75%.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets